# US 2003/0225100 A1 · Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method of preparing same and compositions containing same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225100 A1
- Document ID: US20030225100A1
- Status: Published application
- Kind: A1
- Application number: 10/362,324
- Filed: 2003-02-20
- Published: 2003-12-04
- Earliest claimed: 2000-08-23
- Assignees: Sanofi-Synthelabo
- Inventors: Jean-Louis Assens; Claude Bernhart; Frederique Cabanel-Haudricourt; Patrick Gautier; Dino Nisato
- Web page: https://patentgrep.com/patent/US20030225100A1

## CPC

- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/02: Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 35/00: Antineoplastic agents
- C07D 223/14: condensed with carbocyclic rings or ring systems
- C07D 307/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 307/79: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D 307/80: Radicals substituted by oxygen atoms
- C07D 407/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 471/08: Bridged systems
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Benzothiophenes and related compounds of formula (1), wherein A, B, Z are independently —CH═, —CR4═ or ═N—; X is —S—, —O—, —NH—, —NR2, —CH2—CH2—, CH2—CH2—CH2—, —CH2—O—; —OCH2—, —CH2—S—, —CO—, —SCH2—. —N═CR2— or —R2C═N—; Y is optionally substituted phenyl, alkyl, cycloalkyl, cycloalkenyl, heterocycle or bicyclic ring system; D is —CO—, CR2R3—, —CONH—, —NHCO—, —CR2(OH)—, —CONR2, NOR1 CH—NO2 N—CN —NR2—CO—, —C—, —C—, —C—; E is a single bond, optionally substituted phenyl, heterocycle; Z1 is —(CH2)p W(CH2)q—, —O(CH2)p CR5R6— or —O(CH2)p W(CH2)q; G is —NR7R8, (a), (b), (c), a 5- or 6-membered saturated, unsaturated or partially unsaturated and optionally substituted heterocycle or a bicyclic amine containing 5 to 12 carbon atoms either bridged or fused and optionally substituted and R is halogen, —NR2R3, —NHCOR2, —NHSO2R2, —CR2R3OH, —CONR2R3, —SO2NR2R3, OH, —OR1, —O—COR1; are estrogen agonists which are useful for treating syndromes and diseases caused by estrogen deficiency. 1

## Claims

### Claim 1

Benzofuran or benzothiophene derivatives of general formula:
144
and their pharmaceutically acceptable salts, in which formula:
A represents a linear or branched C1-C5 alkylene group optionally substituted by a hydroxyl group or A represents a group of general formula:
R19—O—R20— (h)
in which R19 and R20, which are identical or different, each represent a linear or branched C1-C4 alkylene group,
R30 and R31, taken together, represent a carbonyl group with the carbon to which they are attached or represent a group of general formula:
—O—R29O— (m)
in which R29 represents a C1-C4 alkylene group,
T represents hydrogen or a C1-C4 alkyl radical,
R represents:
the cyano, hydroxymethyl, formyl or tetrazolyl group,
an ester group of general formula:
145
in which R4 represents a linear or branched C1-C6 alkyl group or a C3-C6 cycloalkyl group,
a carboxyl group of general formula:
146
in which R5 represents hydrogen or an alkali metal atom,
an amide group of general formula:
147
in which R6 and R7, which are identical or different, represent hydrogen or a linear or branched C1-C4 alkyl radical or R6 and R7, when they are taken together, represent a C2-C6 alkylene chain,
a ketone group of general formula:
148
in which R8 represents a C1-C4 alkyl group, an oxime group of general formula:
—CH═N—OR9 (e)
in which R9 represents hydrogen or a C1-C4 alkyl radical,
a carboxyl group of general formula:
149
in which R10 represents a linear or branched C1-C4 alkylene group, R11 represents hydrogen or a C1-C4 alkyl radical, R12 represents a C1-C4 alkyl radical or R11 and R12, when they are taken together, represent a C2-C6 alkylene chain,
a group of general formula:
150
in which R32 and R33, which are identical or different, represent a linear or branched C1-C4 alkyl group,
R1 represents hydrogen, a linear or branched C1-C6 alkyl group, a C3-C6 cycloalkyl group, a benzyl group or a phenyl group optionally substituted by one or more substituents selected from halogen atoms, C1-C4 alkyl groups or C1-C4 alkoxy groups or R1 represents a group of general formula:
151
in which R21 represents a linear or branched C1-C4 alkylene group and R22 represents a linear or branched C1-C4 alkyl group or R1 represents a group of general formula:
—R23—OH (j)
in which R23 represents a linear or branched C1-C6 alkylene group,
R2 and R3, which are identical or different, represent hydrogen, a linear or branched C1-C6 alkyl group optionally substituted by one or more halogen atoms or by a pyrrolidinyl group, a C3-C6 cycloalkyl group or a group of general formula:
—R24—O—R25 (k)
in which R24 represents a linear or branched C1-C4 alkylene group and R25 represents a linear or branched C1-C4 alkyl group,
or R2 and R3, when they are taken together, represent a linear or branched C3-C10alkylene group or represent, with the nitrogen atom to which they are attached, a group of general formula:
152
in which:
R26, R27 and R28, which are identical or different, represent hydrogen, or a linear or branched C1-C4 alkyl group, or
R26 represents hydrogen or a linear or branched C1-C4 alkyl group and R27 and R28, when they are taken together, represent a linear or branched C1-C4 alkylene group,
W, W′ and Z are such that:
when W and W′, which are identical, represent CH, Z represents —O— or —S—,
when W represents CH and W′ represents C—R13, Z represents
153
, R14, R13 and R14 being identical or different and representing hydrogen, a halogen atom, a C1-C4 alkyl radical or a C1-C4 alkoxy radical,
X represents —O— or —S—,
these benzofuran or benzothiophene derivatives being in the form of individual isomers or of mixtures of the latter.

### Claim 2 (depends on 1)

Benzofuran or benzothiophene derivatives according to claim 1, characterized in that A represents a linear or branched C1-C5 alkylene group.

### Claim 3 (depends on 1, 2)

Benzofuran or benzothiophene derivatives according to claim 1 or 2, characterized in that R1 represents hydrogen, a linear or branched C1-C6 alkyl group, a C3-C6 cycloalkyl group, a benzyl group or a phenyl group optionally substituted by one or more substituents selected from halogen atoms, C1-C4 alkyl groups or C1-C4 alkoxy groups.

### Claim 4

Benzofuran or benzothiophene derivatives according to any one of the preceding claims of general formula:
154
and their pharmaceutically acceptable salts, in which:
A represents a linear or branched C1-C5 alkylene group,
T represents hydrogen or a C1-C4 alkyl radical,
R represents:
the cyano, hydroxymethyl, formyl or tetrazolyl group,
an ester group of general formula:
155
in which R4 represents a C1-C6 alkyl or C3-C6 cycloalkyl group,
a carboxyl group of general formula:
156
in which R5 represents hydrogen or an alkali metal atom,
an amide group of general formula:
157
in which R6 and R7, which are identical or different, represent hydrogen or a linear or branched C1-C4 alkyl radical or R6 and R7, when they are taken together, represent a C2-C6 alkylene chain,
a ketone group of general formula:
158
in which R8 represents a C1-C4 alkyl group,
an oxime group of general formula:
—CH═N—OR9 (e)
in which R9 represents hydrogen or a C1-C4 alkyl radical,
a carboxyl group of general formula:
159
in which R10 represents a C1-C4 alkylene group, R11 represents hydrogen or a C1-C4 alkyl radical and R12 represents a C1-C4 alkyl radical or R11 and R12, when they are taken together, represent a C2-C6 alkylene chain,
R1 represents hydrogen, a linear or branched C1-C6 alkyl group, a C3-C6 cycloalkyl group, a benzyl group or a phenyl group optionally substituted by one or more substituents selected from halogen atoms, C1-C4 alkyl groups or C1-C4 alkoxy groups,
R2 and R3, which are identical or different, represent hydrogen, a linear or branched C1-C6 alkyl group or a C3-C6 cycloalkyl group,
or R2 and R3, when they are taken together, represent a linear or branched C3-C10alkylene group,
W, W′ and Z are such that:
when W and W′, which are identical, represent CH, Z represents —O— or —S—,
when W represents CH and W′ represents C—R13, Z represents
160
R13 and R14 being identical or different and representing hydrogen, a halogen atom, a C1-C4 alkyl radical or a C1-C4 alkoxy radical, X represents —O— or —S—, these benzofuran or benzothiophene derivatives being in the form of individual isomers or of mixtures of the latter.

### Claim 5

Benzofuran or benzothiophene derivatives according to any one of the preceding claims, characterized in that R represents the isopropoxycarbonyl group.

### Claim 6

Benzofuran or benzothiophene derivatives according to any one of the preceding claims, characterized in that R1 and/or R2 and/or R3 represent the n-butyl group.

### Claim 7

Benzofuran or benzothiophene derivatives according to any one of the preceding claims, characterized in that X represents —O—.

### Claim 8

Benzofuran or benzothiophene derivatives according to any one of the preceding claims, in which:
161
represents the benzoyl group.

### Claim 9

Benzofuran or benzothiophene derivatives according to any one of the preceding claims, in which:
162
represents the benzoyl group substituted in the 4-position by an -A- group.

### Claim 10

Benzofuran or benzothiophene derivatives according to any one of the preceding claims, characterized in that R1 represents the n-butyl group, A represents the propylene group and R2 and R3, which are identical, represent the n-butyl group.

### Claim 11

Isopropyl 2-butyl-3-[4-[3-(dibutylamino)propyl]benzoyl]-1-benzofuran-5-carboxylate and its pharmaceutically acceptable salts.

### Claim 12

Isopropyl 2-butyl-6-methyl-3-[4-[3-(dibutylamino)propyl]benzoyl]-1-benzofuran-5-carboxylate and its pharmaceutically acceptable salts.

### Claim 13

Benzofuran or benzothiophene derivatives according to any one of the preceding claims, in which the pharmaceutically acceptable salt is chosen from maleate, fumarate, methanesulphonate, benzoate, ascorbate, pamoate, succinate, hexamate, bismethylenesalicylate, acetate, propionate, tartrate, salicylate, citrate, gluconate, lactate, malate, cinnamate, mandelate, citraconate, aspartate, palmitate, stearate, itaconate, glycolate, p-aminobenzoate, glutamate, benzenesulphonate, p-toluenesulphonate and theophyllineacetate salts and the salts formed from an amino acid, such as the lysine or histidine salt.

### Claim 14

Isopropyl 2-butyl-3-[4-[3-(dibutyl-amino)propyl]benzoyl]-1-benzofuran-5-carboxylate fumarate.

### Claim 15

Benzofuran or benzothiophene derivatives according to any one of the preceding claims, in which the pharmaceutically acceptable salt is chosen from the hydrochloride, hydrobromide, sulphate, sulphamate, phosphate and nitrate salts.

### Claim 16

Isopropyl 2-butyl-3-[4-[3-(dibutylamino)propyl]benzoyl]-1-benzofuran-5-carboxylate sulphate.

### Claim 17 (depends on 1)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 1 in which R represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f), characterized in that a compound of general formula:
163
in which R′ represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f) and R1, T and X have the same meaning as in claim 1, is reacted with a halide of general formula:
164
in which A, R2, R3, W, W′ and Z have the same meaning as in claim 1 and Hal represents a halogen atom, the reaction taking place in the presence of a Lewis acid, which gives the desired compounds in the free base form, which base can be reacted, if necessary, with an organic or inorganic acid to form a pharmaceutically acceptable salt.

### Claim 18 (depends on 1)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 1 in which R represents a group (b), characterized in that a compound of general formula:
165
in which A, R1, R2, R3, R4, T, W, W′, X and Z have the same meaning as in claim 1, is saponified in the presence of an alkali metal hydroxide, which gives, in the free base form, the desired compounds of formula (1) in which R5 represents an alkali metal atom, which compounds are treated, if necessary, with a strong acid, which gives, in the free base form, the desired compounds of formula (1) in which R5 represents hydrogen, it being possible for the free base thus formed, if necessary, to be treated with an appropriate organic or inorganic acid to produce a pharmaceutically acceptable salt.

### Claim 19 (depends on 1)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 1 in which R represents the hydroxymethyl group, characterized in that a ketal of general formula:
166
in which A, R1, R2, R3, T, X, W, W′ and Z have the same meaning as in claim 1, is deprotected by means of pyridine p-toluenesulphonate, which gives the derivative compounds in the free base form, which base can be reacted, if necessary, with an organic or inorganic acid to form a pharmaceutically acceptable salt.

### Claim 20 (depends on 1)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 1 in which R represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f) and R2 and R3, which are identical, each represent hydrogen, characterized in that an azide of general formula:
167
in which R′ represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f) and A, R1, T, X, W, W′ and Z have the same meaning as in claim 1, is treated with triphenylphosphine, which gives the desired compounds in the free base form, which base can be reacted, if necessary, with an organic or inorganic acid to form a pharmaceutically acceptable salt.

### Claim 21 (depends on 1)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 1 in which R represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f) and A represents a linear or branched C3-C5 alkylene group or a group (h), characterized in that a ketone compound of general formula:
168
in which R′ represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f), A′ represents a linear or branched C3-C5 alkylene group, Hal represents a halogen atom and R1, T, W, W′, X and Z have the same meaning as in claim 1, is reacted with a compound of general formula:
169
in which R2 and R3 have the same meaning as in claim 1, the reaction taking place in the presence of a basic agent or an excess of compound of formula (8), which gives the desired compounds in the free base form, which base can be reacted, if necessary, with an organic or inorganic acid to form a pharmaceutically acceptable salt.

### Claim 22 (depends on 1)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 1 in which R represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f), R2 represents hydrogen or a linear or branched C1-C6 alkyl group and R3 represents a linear or branched C1-C6 alkyl group, characterized in that an amine of general formula:
170
in which R′ represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f) and A, R1, T, X, W, W′ and Z have the same meaning as in claim 1, is reacted with an aldehyde of general formula:
171
in which R′2 represents hydrogen or a C1-C5 alkyl radical, in the presence of sodium triacetoxyborohydride, to give the desired compounds in the free base form, which base can be reacted, if necessary, with an organic or inorganic acid to form a pharmaceutically acceptable salt.

### Claim 23 (depends on 1)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 1 in which R represents a group (c), characterized in that a compound of general formula:
172
in which A, R1, R2, R3, T, W, W′, X and Z have the same meaning as in claim 1, is reacted, after protection of the amine functional group when R2 and/or R3 represent hydrogen, the reaction taking place with a halogenating agent to produce an acyl halide, which halide is subsequently treated with a compound of general formula:
173
in which R6 and R7 have the same meaning as in claim 1, and then, if necessary, the compound formed is deprotected, which gives the desired compounds in the free base form, it being possible for the free base thus formed, if necessary, to be treated with an appropriate organic or inorganic acid to produce a pharmaceutically acceptable salt.

### Claim 24 (depends on 1)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 1 in which R represents a group (a), characterized in that a compound of general formula:
174
n which A, R1, R2, R3, T, W, W′, X and Z have the same meaning as in claim 1, is reacted, after protection of the amine functional group when R2 and/or R3 represent hydrogen, the reaction taking place with a halogenating agent to produce an acyl halide, which halide is subsequently treated with an alcohol of general formula:
R4—OH (13)
in which R4 has the same meaning as in claim 1, and then, if necessary, the compound formed is deprotected, which gives the desired compounds in the free base form, it being possible for the free base thus formed, if necessary, to be treated with an appropriate organic or inorganic acid to produce a pharmaceutically acceptable salt.

### Claim 25 (depends on 1)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 1 in which R represents a group (c) in which R6 and R7 each represent hydrogen, characterized in that a compound of general formula:
175
in which A, R1, R2, R3, T, W, W′, X and Z have the same meaning as in claim 1, is hydrolysed in the presence of a strong acid, which gives the desired compounds in the free base form, it being possible for the free base thus formed, if necessary, to be treated with an appropriate organic or inorganic acid to produce a pharmaceutically acceptable salt.

### Claim 26 (depends on 1)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 1 in which R represents a group (f) of the primary dialkylaminoalkyl type, characterized in that a compound of general formula:
176
in which A, R1, R2, R3, T, W, W′, X and Z have the same meaning as in claim 1, is reacted, after protection of the amine functional group when R2 and/or R3 represent hydrogen, with an alcohol of general formula:
177
in which R11 and R12 have the same meaning as in claim 1 and R10 represents a linear C1-C4 alkylene group, the reaction taking place in the presence of carbonyldiimidazole and of 1,8-diazabicyclo[5.4.0]undec-7-ene, and then, if necessary, the compound formed is deprotected, which gives the desired compounds in the free base form, which base can be reacted, if necessary, with an organic or inorganic acid to form a pharmaceutically acceptable salt.

### Claim 27 (depends on 1)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 1 in which R represents a group (f) of the secondary or tertiary dialkylaminoalkyl type, characterized in that a compound of general formula:
178
in which A, R1, R2, R3, T, W, W′, X and Z have the same meaning as in claim 1, is reacted, after protection of the amine functional group when R2 and/or R3 represent hydrogen, with a halogenating agent to produce an acyl halide, which halide is subsequently treated with an alcohol of general formula:
179
in which R11 and R12 have the same meaning as in claim 1 and R10 represents a secondary or tertiary C2-C4 alkylene group, and then, if necessary, the compound formed is deprotected, which gives the compounds of formula (1) in the hydrohalide form or in the free base form, which hydrohalide can be treated, if necessary, with a basic agent to produce the desired compounds in the free base form, which base can be reacted, if necessary, with an organic or inorganic acid to form a pharmaceutically acceptable salt.

### Claim 28 (depends on 1)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 1 in which R represents the tetrazolyl group, characterized in that a compound of general formula:
180
in which A, R1, R2, R3, T, W, W′, X and Z have the same meaning as in claim 1, is reacted with a tri(C1-C4 alkyl)azidotin, which gives the desired compounds in the free base form, it being possible for the free base thus formed, if necessary, to be treated with an appropriate organic or inorganic acid to produce a pharmaceutically acceptable salt.

### Claim 29 (depends on 1)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 1 in which R represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f) and in which R2 and R3, which are different, each represent a linear or branched C1-C6 alkyl group or a C3-C6 cycloalkyl group, by reacting a compound of general formula:
181
in which A, R1, R2, T, W, W′, X and Z have the same meaning as in claim 1 and R′ represents the cyano group, the formyl group, a group (a), a group (d), a group (e) or a group (f) and R′3 represents a linear or branched C1-C6 alkyl group or a C3-C6 cycloalkyl group, with a halide of general formula:
Hal-R″2 (17)
in which Hal represents a halogen atom and R12 represents a linear or branched C1-C6 alkyl group or a C3-C6 cycloalkyl group, the reaction taking place in the presence of a basic agent, which gives the derivative compounds in the free base form, it being possible for the free base thus formed, if necessary, to be treated with an appropriate organic or inorganic acid to produce a pharmaceutically acceptable salt.

### Claim 30 (depends on 17, 18, 20, 21)

Process for the preparation of benzofuran or benzothiophene derivatives according to claim 17, 18, 20 or 21, characterized in that the protection of the amine functional group is carried out by means of 9-fluorenylmethyl chloroformate and the deprotection is carried out by treatment by means of a secondary amine.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

Medicament, characterized in that it comprises a benzofuran or benzothiophene derivative or a pharmaceutically acceptable salt of the latter according to any one of claims 1 to 16.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

Pharmaceutical or veterinary composition, characterized in that it comprises, as active principal, at least one benzofuran or benzothiophene derivative or a pharmaceutically acceptable salt of the latter according to any one of claims 1 to 16, in combination with an appropriate excipient or pharmaceutical vehicle.

### Claim 33 (depends on 32)

Pharmaceutical or veterinary composition according to claim 32 for the treatment of pathological syndromes of the cardiovascular system.

### Claim 34 (depends on 32, 33)

Pharmaceutical or veterinary composition according to claim 32 or 33 for the treatment of angina pectoris, hypertension, atrial, ventricular or supraventricular arrhythmia, cerebral circulatory insufficiency, cardiac insufficiency or myocardial infarction, complicated or not complicated by cardiac insufficiency, or for the prevention of post-infarction mortality.

### Claim 35 (depends on 32, 33, 34)

Pharmaceutical or veterinary composition according to any one of claims 32 to 34, characterized in that it comprises from 50 to 500 mg of active principal.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

Use of at least one benzofuran or benzothiophene derivative or of a pharmaceutically acceptable salt of the latter according to any one of claims 1 to 16 for the manufacture of a medicament intended for the treatment of pathological syndromes of the cardiovascular system.
